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Death from stroke in Europe: if you can’t
measure it, you can’t improve it
Chris P. Gale1* and Barbara Casadei2
1Clinical and Population Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; and 2Division of Cardiovascular
5 Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford & NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
Foundation Trust, UK
This editorial refers to ‘Epidemiology report: trends in sex-
specific cerebrovascular disease mortality in Europe based
10 on WHO mortality data’, by X.X. Shah et al., doi:10.1093/
eurheartj/ehy378.
Stroke is a devastating and mostly preventable disease. Across
Europe, it accounts for over one in ten of all deaths each year and is
the third leading cause of disability-adjusted years lost.1 Worldwide,
15 as in Europe, stroke is the second largest single cause of death after is-
chaemic heart disease, with a greater burden in developing coun-
tries.2 For those aged <65 years, stroke, joint with breast cancer, is
the second most common cause of death in women, and the third
most common in men, after ischaemic heart disease and lung cancer.1
20 International data depict a decline in stroke mortality, which is evi-
dent primarily in Western countries.3 Yet, little is known about tem-
poral trends in stroke-related mortality across Europe and,
specifically, for the ischaemic, haemorrhagic, and subarachnoid sub-
types of stroke.
25 In this issue of the European Heart Journal, Shah and colleagues
evaluate the temporal trends in all-cause mortality after stroke in 51
countries of the World Health Organization European region.4
Between 1980 and 2016, the investigators studied age-standardized
mortality rates according to the recognized International
30 Classification of Disease-10 codes for stroke, and used Joinpoint re-
gression to determine if and where statistically significant inflexion
points occurred. The breadth of the data, as well as the numbers of
cases (e.g. nearly 1 million deaths following stroke), permit the inves-
tigation of several important questions.
35 During the 37 years of study, stroke-related mortality declined
across Europe; the median annual percentage change for included
countries was -2.7% for men and -2.7% for women. This was not,
however, the case for all countries or all stroke subtypes. The decline
in death following stroke was only evident in 34 (67%) countries for
40 men and women, with declines being more frequent and steeper in
Western Europe and least frequent and less steep in Central Asia.
Notably, over the full study period there was in increase in deaths fol-
lowing stroke in Macedonia. Temporal improvements were more
frequently seen for haemorrhagic stroke (with the greatest decline in
45Central Asia), followed by ischaemic stroke, and then subarachnoid
haemorrhage (each with the greatest decline inWestern Europe).
Perhaps more alarming, is the evidence of a recent plateauing
among ten countries, and a statistically significant upturn in four coun-
tries (Azerbaijan, Georgia, Tajikistan and Uzbekistan), in deaths fol-
50lowing stroke. Such recent increases in death following stroke were
more frequent for ischaemic stroke and subarachnoid haemorrhage
than for haemorrhagic stroke.
Importantly, Shah et al. provide data on all-cause mortality follow-
ing stroke in Europe as a whole, and up to the year 2016. Moreover,
55higher resolution insights are gained as to the changing spatial and
temporal burden of mortality for stroke subtypes. The decline in
deaths following stroke is encouraging because of the sheer volume
of the population that cerebrovascular disease encompasses.
Nonetheless, two fundamental questions remain unanswered; what
60is responsible for the decline in mortality following stroke across
Europe, and why has there been a recent plateau or increase in
stroke-related mortality in some European countries?
The reasons for the decline in stroke-related mortality are not
completely understood. It is likely that it is due to a combination of
65reduced incidence of index and recurrent stroke as well as lower
case fatality rates.5 Such progress in population outcomes is consist-
ent with international improvements in cardiovascular risk factor
control. Indeed, the international decline in death following stroke
mirrors that seen for cardiovascular disease mortality that has also, in
70part, been attributable to changes in its determinants.1,6
A reduction in stroke incidence will have a direct impact on the
stroke-related mortality rates. It has been suggested that the under-
standing of the causal relationship between blood pressure and vas-
cular events, and the treatment of hypertension at scale has had a
75substantial influence on the decline in stroke mortality.7 Clearly,
other factors are also relevant, including the detection and treatment
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of diabetes mellitus and dyslipidaemia, smoking cessation, diet and
physical exercise.8 The importance of oral anticoagulants rather than
aspirin in stroke prevention among patients in atrial fibrillation at high
risk of stroke has had increasing emphasis in national and internation-
5 al guidelines, and over time there has been an increase in incident
cases of atrial fibrillation prescribed an oral anticoagulant.9
Undoubtedly, this will have also contributed to the decline in the inci-
dence of stroke.10
The decline in the incidence of recurrent stroke is an important
10 factor contributing to the decline in death following stroke. Up to
18% of strokes within the first year and 9.5% in the first 5 years are
recurrent and convey high early mortality rates.11,12 The decline in
recurrent stroke rates largely results from evidence for and the sub-
sequent implementation of secondary preventive therapies.
15 Moreover, it is estimated that four-fifths of recurrent vascular events
in patients with stroke may be prevented by the application of a com-
bined lifestyle and pharmacotherapeutic approach.13
Improved tools for brain imaging evaluation (enabling us to know
what to treat), endovascular treatment modalities (more effective
20 therapies), and greater stroke systems (improved access to and deliv-
ery of care) have all advanced stroke management and thus contrib-
uted to favourable trends in stroke outcomes. For example,
compared with 35 years ago, it is now recommended that non-
contrast computed tomography (CT) should be provided (and ex-
25 peditiously from time of arrival in the Emergency Department) for all
patients presenting to hospital with suspected stroke.14 Doing so
enables the rapid detection of intracranial haemorrhage and there-
fore the avoidance of antithrombotics in these patients, the diagnosis
of stroke in those presenting with puzzling signs, and risk stratification
30for endovascular treatment.
The INTERSTROKE study found that the use of evidence-based
treatments, diagnostics, and stroke units was less commonly available
in low and middle income countries.15 A similar pattern has been
described within the UK, whereby those at higher risk for stroke
35were less frequently receiving oral anticoagulation.16 This could be
attributed to constraints around infrastructure and education, which,
however, may not entirely explain why inauspicious trends in stroke
case fatalities are also found in higher income countries. Whilst it is
possible that adverse trends may be due to more accurate recording
40of stroke events, one must not discount the increasing population
burden of obesity, diabetes, and hypertension in higher income coun-
tries and the effect this may have on stroke incidence and mortality.
Akin to many epidemiological studies, the research undertaken by
Shah and colleagues has limitations. Many countries did not have data
45that covered the full study period, the recording of death and the def-
inition of its cause varied across the countries, and some had poor
data quality as defined by the World Health Organization. Equally, a
description of death following stroke by age is not presented, which
would offer readers insight into the geographical burden of prema-
50ture deaths due to stroke. Importantly, the study used aggregated
data and we should not, therefore, make inferences about individuals
from country-based statistics.
The fact that there is geographic variation in mortality from stroke
suggests that the opportunity to prevent deaths from stroke has not
55been realized. This concept is underscored by the tailoring of the de-
cline and the upturn in death following stroke in some European
Take home figure Sex-dependent differences in recent trends in cerebrovascular age-standardized mortality rates in Europe.
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countries. Local-level and international quality improvement initia-
tives are therefore needed. In the UK, the National Institute for
Health and Care Excellence recommends opportunistic detection of
atrial fibrillation in patients with co-morbidities who are attending
5 their general practitioner (though currently the National Screening
Programme does not recommended population-based screening be-
cause their review found that it was not clear that those identified as
at risk through screening would benefit from early diagnosis). Given
that the use of primary and secondary prevention pharmacotherapies
10 for stroke has a central role in reducing stroke and subsequent
stroke-related mortality, their implementation will also be key in
ensuring that the temporal decline continues. Equally, the importance
of measuring quality of care through large-scale studies for the devel-
opment of quality improvement cannot be overemphasized.
15 Unless health disparities are addressed and innovative strategies to
change behaviour are developed and adopted, the cerebrovascular
health of the population is unlikely to improve.
Conflict of interest: none declared.
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